AOD-9604 vs Semaglutide
AOD-9604 and Semaglutide both appear in metabolic and adipose-tissue research, but they target completely different receptors and pathways. AOD-9604 is a growth hormone fragment investigated for direct adipocyte effects; Semaglutide is a GLP-1 receptor agonist that affects appetite signaling, gastric emptying, and glucose handling. The two are often confused as similar despite operating on different axes entirely.
| Property | AOD-9604 | Semaglutide |
|---|---|---|
| Class | Modified GH fragment (177-191) | GLP-1 receptor agonist |
| Receptor | Beta-3 adrenergic (research) | GLP-1 receptor |
| Mechanism (research) | Direct adipocyte lipolysis | Appetite, gastric emptying, glucose |
| Primary research focus | Adipose tissue | Glucose handling, body weight |
| Half-life (reported) | ~30 minutes | ~165 hours (~1 week) |
About AOD-9604
AOD-9604 is a 16-amino acid synthetic fragment derived from the C-terminus of human growth hormone. Research has characterized it for effects on adipose tissue lipolysis in animal models, distinct from the broader growth-promoting effects of full-length growth hormone. Mechanism research has investigated beta-3 adrenergic pathways in adipocytes.
About Semaglutide
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist. Research has characterized it extensively for effects on glucose handling, gastric emptying, appetite regulation, and body weight in clinical research models. Its long half-life of approximately 165 hours allows for once-weekly research protocols.
Which Should Researchers Choose?
The choice depends on the research focus:
- Adipocyte-direct research -> AOD-9604.
- Glucose handling or appetite research -> Semaglutide.
- Body composition broadly -> Different mechanisms; not interchangeable in research design.
Shop these compounds
Frequently Asked Questions
Are AOD-9604 and Semaglutide similar?
No. They target different receptors and mechanisms entirely.
Can they be researched together?
Some research protocols investigate combinations since the mechanisms don't overlap.
Are these FDA approved?
Semaglutide has clinical approval in some indications. AOD-9604 is an investigational research compound.